Lead Product(s) : Alteplase
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Boehringer Ingelheim Focus Covid-19 Therapy Research on Development of Alteplase
Details : It evaluated efficacy and safety of two different dosing regimens of intravenous alteplase given for up to 5 days on top of best available medical management (standard of care (SOC)), compared with SOC alone.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 26, 2021
Lead Product(s) : Alteplase
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Alteplase
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A team of doctor at the University of Colorado are conducting research into the drug Alteplase (or tPA) to test its efficacy to dissolve clots in the vessels of a COVID-19 patient’s lungs.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 06, 2020
Lead Product(s) : Alteplase
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
